Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

In Vivo Targeting of Escherichia coli with Vancomycin-Arginine

Lewis F. Neville, Itamar Shalit, Peter A. Warn, Marc H. Scheetz, Jiuzhi Sun, Madeline B. Chosy, Paul A. Wender, Lynette Cegelski, Jacob T. Rendell
Lewis F. Neville
aSuperTrans Medical Ltd., Ness Ziona, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lewis F. Neville
Itamar Shalit
aSuperTrans Medical Ltd., Ness Ziona, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Warn
bMagic Bullet Consulting, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc H. Scheetz
cDepartment of Pharmacy Practice, Chicago College of Pharmacy and Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc H. Scheetz
Jiuzhi Sun
dDepartment of Chemistry, Stanford University, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madeline B. Chosy
dDepartment of Chemistry, Stanford University, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Wender
dDepartment of Chemistry, Stanford University, Stanford, California, USA
eDepartment of Chemical and Systems Biology, Stanford University, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynette Cegelski
dDepartment of Chemistry, Stanford University, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lynette Cegelski
Jacob T. Rendell
aSuperTrans Medical Ltd., Ness Ziona, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02416-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC towards Escherichia coli, including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml. Addition of 8 times the MIC of V-r to E. coli was acutely bactericidal and associated with a low frequency of resistance (<2.32 × 10−10). In vivo, V-r markedly reduced E. coli burden by >7 log10 CFU/g in a thigh muscle model. These data warrant further development of V-r in combatting E. coli, including resistant forms.

INTRODUCTION

Novel antibiotics are desperately needed to combat priority 1 or urgent-threat pathogens (1–3). With only four new classes of antibiotics introduced into the market since the early 1960s (4), structural modifications of current antibiotics provide an attractive and possibly speedier approach to fulfill this significant unmet clinical need. Vancomycin is a standard-of-care glycopeptide antibiotic for the treatment of Gram-positive infections (5). Numerous reports have demonstrated augmentation of its antimicrobial activity against resistant strains via different chemical modifications (6–9). Furthermore, its molecular structure has been successfully manipulated to create a broader spectrum of activity in the targeting of Gram-negative bacteria via adjuvant, formulation, and cationic/lipophilic interventions (10, 11) or synergy with existing Gram-negative antibiotics (12, 13). Recently, the covalent conjugation of l-arginine to vancomycin, to produce vancomycin-l-arginine (V-R), led to promising Gram-negative properties via a cell wall mode of action (14). These findings encouraged us to further characterize the corresponding diastereomer vancomycin-d-arginine (V-r) in animal models of E. coli infection using the d-isomer of arginine to reduce the risk of conjugate hydrolysis (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Vancomycin and vancomycin-d-arginine (V-r).

V-r was synthesized in a single chemical step from commercially available vancomycin HCl (StruChem, Wujiang City, China) and d-arginine amide dihydrochloride (Aladdin Chemical Co., Shanghai, China). The crude compound was purified and isolated as the corresponding HCl salt at 95% purity by high-performance liquid chromatography based on a previously described procedure (14). Identity was confirmed by 1H nuclear magnetic resonance and time of flight mass spectrometry, and HCl content was quantified by ion-exchange chromatography. In various physicochemical screens, V-r behaved similarly to vancomycin, including no observed cellular cytotoxicity at concentrations ranging from 100 to 750 μM on human erythrocytes, HepG2, and primary renal proximal tubule epithelial cells employing fetal bovine serum-deficient media to negate compound quenching (15) (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Physicochemical properties of vancomycin-arginine (V-r) and vancomycin

MICs were determined in alignment with CLSI guidelines as previously described for V-R and cationic antimicrobial peptides (14, 16). The MIC range of V-r against 29 different E. coli strains was 8 to 16 μg/ml (MIC90, 16 μg/ml), including those with multiple resistance mechanisms (Table 2). The MIC of V-r against the efflux pump mutant strain JW0451-2 was 8 μg/ml, suggesting that V-r is unlikely to be a substrate for efflux in this pathogen. Notably, the MIC of V-r was also 8 μg/ml against two out of five of the Acinetobacter baumannii strains tested. In comparison, the MICs of vancomycin were significantly higher, at 64 to 256 μg/ml, against all E. coli and A. baumannii strains tested. Importantly, the antimicrobial potency of V-r towards a number of Gram-positive bacteria remained intact (Table 2). In frequency-of-resistance (FoR) assays at 8 times the MIC of V-r (128 μg/ml), E. coli ATCC 25922 demonstrated an extremely low FoR, at <2.32 × 10−10, which is similar to or lower than those with standard-of-care therapies, such as ciprofloxacin (17, 18). Time-kill assays were performed against uropathogenic E. coli strains, including the sequence type 131 (ST131) NCTC 13341 isolate. V-r, but not vancomycin, demonstrated rapid bactericidal activity to limits of detection (i.e., 100 CFU/ml) within 1 or 4 h of exposure, and this was maintained up to 24 h (Fig. 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Antimicrobial susceptibility profiles of V-r and vancomycin

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Time-kill of vancomycin-arginine (V-r) and vancomycin against E. coli uropathogens UTI89 and NCTC 13441.

Plasma pharmacokinetics (PK) of V-r after subcutaneous (s.c.) administration (20 and 121 mg/kg) was determined in naive male CD-1 mice (n = 3/group) using liquid chromatography-tandem mass spectrometry for analysis with a lower limit of quantitation of 5 ng/ml (Table 3). V-r displayed first-order elimination, similar to vancomycin, after s.c. administration (19, 20). Prior to efficacy studies, a single s.c. administration of V-r was shown to be well tolerated in male CD-1 mice (n = 3) at the highest dose tested (800 mg/kg).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3

PK parameters of V-r in CD-1 mice after s.c. administration

Using a screening-based strategy, preliminary proof-of-concept studies with V-r employed an abbreviated 9-h thigh muscle infection model in male CD-1 mice rendered neutropenic (21). To that end, an E. coli ATCC 25922 isolate was inoculated at 9.7 × 104 CFU into both thigh muscles per mouse (n = 5 per experimental group). V-r was administered s.c. every 2 h (110 to 880 mg/kg total dose) starting 1 h postinfection. At 9 h, thigh homogenates were prepared, and CFU were enumerated after culture on CLED (cystine-, lactose-, and electrolyte-deficient) agar. Compared to pretreatment and vehicle burdens of 5.1 ± 0.2 and 7.1 ± 0.1 log10 CFU/g tissue, respectively, V-r exhibited a dose-dependent reduction in bacterial burden of 1.2 to 3.4 log10 compared with vehicle (Kruskal-Wallis one-way analysis of variance using StatsDirect Statistical Analysis Software) (Table 4). V-r doses at 440 and 880 mg/kg afforded 1.0- and 1.3-log10 reductions below stasis, respectively, with an extrapolated static dose of 215 mg/kg. As anticipated, vancomycin failed to significantly impact E. coli burden at a dose equivalent to the highest dose of V-r. In a 24-h thigh muscle infection model, E. coli UTI89 was inoculated at 7.8 × 104 CFU into one thigh muscle per mouse (n = 5 to 8 per group) and treated with V-r (total dose, 200 to 1,400 mg) using an every-6-h dosing regimen from 1 h postinfection. All doses of >200 mg/kg significantly reduced burden below stasis by up to 2.7 log10 CFU/g. These bactericidal effects of V-r were statistically superior to those of ciprofloxacin, which induced a 1.4 log10 reduction from stasis (Fig. 3 and Table 5). Overall, V-r caused an ∼4 to 7.5 log10 reduction in bacterial burden, compared with vehicle control, over the entire dose range.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Efficacy of V-r in reducing E. coli UTI89 burden in a 24-h thigh muscle infection model in neutropenic CD-1 mice.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 4

Efficacy of V-r in an E. coli ATCC 25922 thigh muscle infection model (9 h) in neutropenic CD-1 mice

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 5

Efficacy of V-r in reducing E. coli UTI89 burden in 24-h thigh muscle infection model in neutropenic CD-1 mice

The MIC data confirm previous findings that the coupling of arginine with vancomycin bestows significant antimicrobial activity of the V-r conjugate against E. coli infection while remaining effective against methicillin-resistant Staphylococcus aureus (MRSA) (14). Such in vitro findings were effectively translated into thigh muscle infection models, where a total 24-h dose of 250 mg/kg V-r reduced E. coli burden to pretreatment (stasis) levels. Since area under the curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) is the primary PK/pharmacodynamic predictor of vancomycin (5), this static dose corresponds to a total AUC/MIC of 47.3. Based on a free (f) fraction of 35%, as determined in plasma protein binding studies (Table 1), the fAUC/MIC of V-r was 16.5. As an approximation of exposure using allometric scaling (22), this would be equivalent to a human dose of ∼20 mg/kg, with a dose of 28 mg/kg required to elicit an additional 1-log10 kill. Such allometric doses of V-r are in line with the daily and loading doses of vancomycin in humans (5).

The positive efficacy data support the notion that the cationic feature of arginine within V-r allows for breaching of the stubborn outer membrane of E. coli isolates and possibly other Gram-negative bacteria (14). The sequelae of events leading to V-r-mediated E. coli eradication likely involve (i) improved cell surface association with negatively charged groups, (ii) effective translocation across the outer membrane leading to enhanced drug uptake, and (iii) disruption of peptidoglycan synthesis within the periplasmic space (6, 14). To our knowledge, the current findings describe the first report of a marked abrogation of E. coli burden in vivo with a minimally modified vancomycin-cationic transporter conjugate. Previously, it was reported that vancomycin-QC14, a strongly lipophilic/cationic molecule, reduced thigh muscle infection of a carbapenem-resistant A. baumannii strain (23). Because V-r was highly effective in time-kill assays against E. coli NCTC 13441, a pandemic uropathogenic clone (24), a logical next step would be to evaluate the conjugate in a model of urinary tract infection (UTI). Based on the high renal elimination of vancomycin in humans (25) in a nonmetabolized form (26), it is reasonable to hypothesize that V-r may drive a highly targeted therapeutic intervention to combat E. coli-associated UTIs.

These data further underscore a precedent for creating a novel Gram-negative active agent by transforming a commonly used and selective Gram-positive antibiotic by introducing certain cationic features through a simple and scalable synthesis protocol (14). Such an approach, in consort with effective in silico predictions (27, 28), might expedite antibiotic development and increase the overall probability of success of drug candidates. Most important, this would help to arrest the insidious pandemic of difficult-to-treat bacterial infections.

ACKNOWLEDGMENTS

We are grateful to Patricia A. Bradford (Antimicrobial Specialists LLC, USA) for critically reviewing the manuscript. We also thank D. Corbett and J. Gould (Evotec, UK), D. Turner (Cyprotex, UK), Y. Huang, M. Gassen, and J. Li (WuXi AppTec, China) and their respective teams for support with synthesis, in vitro, and animal studies described herein.

All studies described in this report were financed solely by SuperTrans Medical Ltd. (Israel).

Stanford University has filed patent applications on this and related technology, supported in part by the National Institutes of Health grants R01GM117278 (L.C.) and NIH-CA031845 and NSF CHE-1566423 (P.A.W.), which has been licensed by SuperTrans Medical for the treatment of bacterial infectious diseases. P.A.W. and L.C. serve as consultants to the company.

FOOTNOTES

    • Received 16 November 2020.
    • Returned for modification 19 December 2020.
    • Accepted 25 December 2020.
    • Accepted manuscript posted online 19 January 2021.
  • Copyright © 2021 Neville et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    Centers for Disease Control and Prevention. 2019. CDC’s antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention, Atlanta, GA.
  2. 2.↵
    1. Tacconelli E,
    2. Magrini N
    . 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.
  3. 3.↵
    1. Peri AM,
    2. Doi Y,
    3. Potoski BA,
    4. Harris PNA,
    5. Paterson DL,
    6. Righi E
    . 2019. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis 94:413–425. doi:10.1016/j.diagmicrobio.2019.01.020.
    OpenUrlCrossRef
  4. 4.↵
    1. De Oliveira DMP,
    2. Forde BM,
    3. Kidd TJ,
    4. Harris PNA,
    5. Schembri MA,
    6. Beatson SA,
    7. Paterson DL,
    8. Walker MJ
    . 2020. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 33:e00181-19. doi:10.1128/CMR.00181-19.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Rybak MJ,
    2. Le J,
    3. Lodise TP,
    4. Levine DP,
    5. Bradley JS,
    6. Liu C,
    7. Mueller BA,
    8. Pai MP,
    9. Wong-Beringer A,
    10. Rotschafer JC,
    11. Rodvold KA,
    12. Maples HD,
    13. Lomaestro BM
    . 2020. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77:835–864. doi:10.1093/ajhp/zxaa036.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Antonoplis A,
    2. Zang X,
    3. Huttner MA,
    4. Chong KKL,
    5. Lee YB,
    6. Co JY,
    7. Amieva MR,
    8. Kline KA,
    9. Wender PA,
    10. Cegelski L
    . 2018. A dual-function antibiotic-transporter conjugate exhibits superior activity in sterilizing MRSA biofilms and killing persister cells. J Am Chem Soc 140:16140–16151. doi:10.1021/jacs.8b08711.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Umstätter F,
    2. Domhan C,
    3. Hertlein T,
    4. Ohlsen K,
    5. Mühlberg E,
    6. Kleist C,
    7. Zimmermann S,
    8. Beijer B,
    9. Klika KD,
    10. Haberkorn U,
    11. Mier W,
    12. Uhl P
    . 2020. Vancomycin resistance is overcome by conjugation of polycationic peptides. Angew Chem Int Ed Engl 59:8823–8827. doi:10.1002/anie.202002727.
    OpenUrlCrossRef
  8. 8.↵
    1. Umstätter F,
    2. Domhan C,
    3. Hertlein T,
    4. Ohlsen K,
    5. Mühlberg E,
    6. Kleist C,
    7. Zimmermann S,
    8. Beijer B,
    9. Klika KD,
    10. Haberkorn U,
    11. Mier W,
    12. Uhl P
    . 2020. Corrigendum: vancomycin resistance is overcome by conjugation of polycationic peptides. Angew Chem Int Ed 59:17326–17326. doi:10.1002/anie.202007022.
    OpenUrlCrossRef
  9. 9.↵
    1. Wu Z-C,
    2. Cameron MD,
    3. Boger DL
    . 2020. Vancomycin C-terminus guanidine modifications and further insights into an added mechanism of action imparted by a peripheral structural modification. ACS Infect Dis 6:2169–2180. doi:10.1021/acsinfecdis.0c00258.
    OpenUrlCrossRef
  10. 10.↵
    1. Blaskovich MAT,
    2. Hansford KA,
    3. Butler MS,
    4. Jia Z,
    5. Mark AE,
    6. Cooper MA
    . 2018. Developments in glycopeptide antibiotics. ACS Infect Dis 4:715–735. doi:10.1021/acsinfecdis.7b00258.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Dhanda G,
    2. Sarkar P,
    3. Samaddar S,
    4. Haldar J
    . 2019. Battle against vancomycin-resistant bacteria: recent developments in chemical strategies. J Med Chem 62:3184–3205. doi:10.1021/acs.jmedchem.8b01093.
    OpenUrlCrossRef
  12. 12.↵
    1. Gordon NC,
    2. Png K,
    3. Wareham DW
    . 2010. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 54:5316–5322. doi:10.1128/AAC.00922-10.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Zhou A,
    2. Kang TM,
    3. Yuan J,
    4. Beppler C,
    5. Nguyen C,
    6. Mao Z,
    7. Nguyen MQ,
    8. Yeh P,
    9. Miller JH
    . 2015. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother 59:276–281. doi:10.1128/AAC.03502-14.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Antonoplis A,
    2. Zang X,
    3. Wegner T,
    4. Wender PA,
    5. Cegelski L
    . 2019. Vancomycin-arginine conjugate inhibits growth of carbapenem-resistant E. coli and targets cell-wall synthesis. ACS Chem Biol 14:2065–2070. doi:10.1021/acschembio.9b00565.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Zink D,
    2. Chuah JKC,
    3. Ying JY
    . 2020. Assessing toxicity with human cell-based in vitro methods. Trends Mol Med 26:570–582. doi:10.1016/j.molmed.2020.01.008.
    OpenUrlCrossRef
  16. 16.↵
    1. Wiegand I,
    2. Hilpert K,
    3. Hancock REW
    . 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163–175. doi:10.1038/nprot.2007.521.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Martinez JL,
    2. Baquero F
    . 2000. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44:1771–1777. doi:10.1128/aac.44.7.1771-1777.2000.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Charrier C,
    2. Salisbury A-M,
    3. Savage VJ,
    4. Moyo E,
    5. Forward H,
    6. Ooi N,
    7. Cheung J,
    8. Metzger R,
    9. McGarry D,
    10. Walker R,
    11. Cooper IR,
    12. Ratcliffe AJ,
    13. Stokes NR
    . 2016. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. J Antimicrob Chemother 71:2831–2839. doi:10.1093/jac/dkw228.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Crandon JL,
    2. Kuti JL,
    3. Nicolau DP
    . 2010. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 54:5115–5119. doi:10.1128/AAC.00062-10.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Lepak AJ,
    2. Zhao M,
    3. Andes DR
    . 2017. Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus. Antimicrob Agents Chemother 61:e00281-17. doi:10.1128/AAC.00281-17.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Everett M,
    2. Sprynski N,
    3. Coelho A,
    4. Castandet J,
    5. Bayet M,
    6. Bougnon J,
    7. Lozano C,
    8. Davies DT,
    9. Leiris S,
    10. Zalacain M,
    11. Morrissey I,
    12. Magnet S,
    13. Holden K,
    14. Warn P,
    15. De Luca F,
    16. Docquier J-D,
    17. Lemonnier M
    . 2018. Discovery of a novel metallo-β-lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 62:e00074-18. doi:10.1128/AAC.00074-18.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    FDA. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Washington, DC. https://www.fda.gov/media/72309/download.
  23. 23.↵
    1. Yarlagadda V,
    2. Manjunath GB,
    3. Sarkar P,
    4. Akkapeddi P,
    5. Paramanandham K,
    6. Shome BR,
    7. Ravikumar R,
    8. Haldar J
    . 2016. Glycopeptide antibiotic to overcome the intrinsic resistance of Gram-negative bacteria. ACS Infect Dis 2:132–139. doi:10.1021/acsinfecdis.5b00114.
    OpenUrlCrossRef
  24. 24.↵
    1. Nicolas-Chanoine M-H,
    2. Bertrand X,
    3. Madec J-Y
    . 2014. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27:543–574. doi:10.1128/CMR.00125-13.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Matzke GR,
    2. Zhanel GG,
    3. Guay DRP
    . 1986. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11:257–282. doi:10.2165/00003088-198611040-00001.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Cao M,
    2. Feng Y,
    3. Zhang Y,
    4. Kang W,
    5. Lian K,
    6. Ai L
    . 2018. Studies on the metabolism and degradation of vancomycin in simulated in vitro and aquatic environment by UHPLC-triple-TOF-MS/MS. Sci Rep 8:15471. doi:10.1038/s41598-018-33826-9.
    OpenUrlCrossRef
  27. 27.↵
    1. Richter MF,
    2. Drown BS,
    3. Riley AP,
    4. Garcia A,
    5. Shirai T,
    6. Svec RL,
    7. Hergenrother PJ
    . 2017. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545:299–304. doi:10.1038/nature22308.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Richter MF,
    2. Hergenrother PJ
    . 2019. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics: challenges in developing broad-spectrum antibiotics. Ann N Y Acad Sci 1435:18–38. doi:10.1111/nyas.13598.
    OpenUrlCrossRef
  29. 29.
    1. Dave RA,
    2. Morris ME
    . 2016. A quantitative threshold for high/low extent of urinary excretion of compounds in humans: threshold for high/low urinary excretion. Biopharm Drug Dispos 37:287–309. doi:10.1002/bdd.2013.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
Lewis F. Neville, Itamar Shalit, Peter A. Warn, Marc H. Scheetz, Jiuzhi Sun, Madeline B. Chosy, Paul A. Wender, Lynette Cegelski, Jacob T. Rendell
Antimicrobial Agents and Chemotherapy Mar 2021, 65 (4) e02416-20; DOI: 10.1128/AAC.02416-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vivo Targeting of Escherichia coli with Vancomycin-Arginine
Lewis F. Neville, Itamar Shalit, Peter A. Warn, Marc H. Scheetz, Jiuzhi Sun, Madeline B. Chosy, Paul A. Wender, Lynette Cegelski, Jacob T. Rendell
Antimicrobial Agents and Chemotherapy Mar 2021, 65 (4) e02416-20; DOI: 10.1128/AAC.02416-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Escherichia coli
Gram-negative bacteria
antibiotic resistance
Arginine
cationic peptides
multidrug resistance
vancomycin conjugate

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596